FDA Grants Fast Track Designation for Balstilimab to Treat Advanced Cervical Cancer

Agenus received approval from the FDA for fast track designation of balstilimab monotherapy and balstilimab and zalifrelimab combination therapy for the treatment of metastatic cervical cancer.

Source: CancerNetwork - April 10, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news